BK0042 Chemical Pharmaceuticals
- 786.234
- +11.505+1.49%
Poinsettia (300723): Short-term performance under pressure, R&D continues to advance
Incident: Yipinna released its 2023 annual report. In 2023, the company achieved operating revenue of 2.503 billion yuan, an increase of 9.79% over the previous year; realized net profit of 185 million yuan, a year-on-year decrease of 36.49%; achieved
Fosun Pharmaceuticals (600196): The first quarter met expectations and expected marginal improvement
The 1Q24 results are in line with our expectations. The company announced 1Q24 results: revenue of 10.157 billion yuan, -7% YoY; attributed/deducted non-net profit of RMB610/609 million, respectively, or -38%/-34% YoY. Business
Express News | Hengrui launches GLP-1R/GIPR dual agonist weight loss phase III study
Solid Earnings Reflect Sichuan Biokin PharmaceuticalLtd's (SHSE:688506) Strength As A Business
Sichuan Biokin Pharmaceutical Co.,Ltd.'s (SHSE:688506) strong earnings report was rewarded with a positive stock price move. Our analysis found some more factors that we think are good for shareholde
Xinhecheng (002001): Net profit attributable to 23 billion yuan decreased by 25.30% year-on-year, optimistic about the growth brought about by the commissioning of new projects
Shinwa Seong released its 2023 annual report. In 2023, the company achieved operating income of 15.117 billion yuan, a year-on-year decrease of 5.13%; realized net profit to mother of 2.704 billion yuan, a year-on-year decrease of 25.30%. 202
Harbin Pharmaceutical Group's (SHSE:600664) Anemic Earnings Might Be Worse Than You Think
The market rallied behind Harbin Pharmaceutical Group Co., Ltd.'s (SHSE:600664) stock, leading do a rise in the share price after its recent weak earnings report. We think that shareholders might be
JiangSu WuZhong Pharmaceutical Development (SHSE:600200) Climbs 5.8% This Week, Taking Five-year Gains to 79%
JiangSu WuZhong Pharmaceutical Development Co., Ltd. (SHSE:600200) shareholders might be concerned after seeing the share price drop 13% in the last month. But that doesn't change the fact that the
Jiangsu Jibeier Pharmaceutical (SHSE:688566) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Jiangsu Jibeier Pharmaceutical Co., Ltd.'s (SHSE:688566) robust earnings report didn't manage to move the market for its stock. Our analysis suggests that shareholders have noticed something concerni
We Think You Should Be Aware Of Some Concerning Factors In ChengDu ShengNuo BiotecLtd's (SHSE:688117) Earnings
The market for ChengDu ShengNuo Biotec Co.,Ltd.'s (SHSE:688117) stock was strong after it released a healthy earnings report last week. While the profit numbers were good, our analysis has found some
North China Pharmaceutical Company.Ltd (SHSE:600812) Strong Profits May Be Masking Some Underlying Issues
North China Pharmaceutical Company.Ltd (SHSE:600812) just released a solid earnings report, and the stock displayed some strength. Despite this, our analysis suggests that there are some factors weak
Xianju Pharmaceutical (002332): Revenue performance in '23 is under pressure, 24Q1 returns to positive growth
Core idea In '23, the company's API sector was affected by increased competition in the industry market. The pharmaceutical side was affected by collection, annual revenue fell 5.9% year on year, net profit after deducting non-return mother fell 12.1% year on year, and revenue profit was under pressure. 24Q1 Receipt
Jingxin Pharmaceutical (002020): Finished drugs are stabilizing and increasing the dosage of new drugs for insomnia can be expected
The impact of the company's generic drug collection is basically clear, and performance is expected to grow steadily. The company promotes levetiracetam tablets, sertraline hydrochloride tablets, dispersible tablets, and salt by establishing a “split line” marketing model centered on the three major channels of neuropsychiatric, cardiovascular, and digestive systems
Xinhecheng (002001) Company Annual Report Review: Net profit attributable to 23 billion yuan of 2.704 billion yuan fell 25.30% year-on-year, optimistic about the growth brought about by the commissioning of new projects
Shinwa Seong released its 2023 annual report. In 2023, the company achieved operating income of 15.117 billion yuan, a year-on-year decrease of 5.13%; realized net profit to mother of 2.704 billion yuan, a year-on-year decrease of 25.30%. 202
Express News | Sinqi Eye Medicine: Aier Eye Hospital Group and others have reached a cooperation with the company and will introduce low-concentration atropine in the near future
Express News | Sinqi Pharmaceutical: After 0.01% atropine sulfate eye drops were approved, the production line was uninterrupted for 24 hours
Express News | Hanyu Pharmaceutical: The total contract order amount for liraglutide preparations and various GLP-1 APIs is nearly 600 million yuan
Huahai Pharmaceutical's Q1 Profit Jumps 57%, Income Up 21%
Zhejiang Huahai Pharmaceutical (SHA:600521) booked a net profit attributable to shareholders of 270.8 million yuan in the first quarter of the year, jumping 56.6% from 172.9 million yuan a year earlie
Jiankai Technology (688356): Short-term product sales are disrupted by multiple factors and the self-research pipeline is progressing in an orderly manner
The 2023 and 2024 quarterly results are in line with our expectations for 2023: revenue of $292 million, -28.26% year over year; net profit to mother of $116 million, or -38.05% year on year; deducting non-net profit 1.
Private Companies Account for 48% of Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) Ownership, While Individual Investors Account for 35%
Key Insights Joincare Pharmaceutical Group IndustryLtd's significant private companies ownership suggests that the key decisions are influenced by shareholders from the larger public A total of 3 in
We Think Youcare Pharmaceutical Group (SHSE:688658) Is Taking Some Risk With Its Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor